Education
About Us
Working with TipRanks
Follow Us
Arch Biopartners (TSE:ARCH)
:ARCH
Total Valuation
Arch Biopartners has a market cap or net worth of C$112.87M. The enterprise value is ―.
Market CapC$112.87M
Enterprise Value―
Share Statistics
Arch Biopartners has 65,621,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,621,370
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arch Biopartners’s return on equity (ROE) is 0.90 and return on invested capital (ROIC) is 230.45%.
Return on Equity (ROE)0.90
Return on Assets (ROA)-4.19
Return on Invested Capital (ROIC)230.45%
Return on Capital Employed (ROCE)0.91
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arch Biopartners is -28.62. Arch Biopartners’s PEG ratio is -3.08.
PE Ratio-28.62
PS Ratio0.00
PB Ratio-25.30
Price to Fair Value-25.80
Price to FCF-40.31
Price to Operating Cash Flow-39.89
PEG Ratio-3.08
Income Statement
In the last 12 months, Arch Biopartners had revenue of 0.00 and earned -3.92M in profits. Earnings per share was -0.06.
Revenue0.00
Gross Profit0.00
Operating Income-3.95M
Pretax Income-4.26M
Net Income-3.92M
EBITDA-3.53M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -2.23M and capital expenditures 3.00, giving a free cash flow of -2.23M billion.
Operating Cash Flow-2.23M
Free Cash Flow-2.23M
Free Cash Flow per Share-0.03
Dividends & Yields
Arch Biopartners pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.93
52-Week Price Change0.58%
50-Day Moving Average1.78
200-Day Moving Average1.79
Relative Strength Index (RSI)46.85
Average Volume (3m)18.30K
Important Dates
Arch Biopartners upcoming earnings date is Jun 3, 2025, TBA Not Confirmed.
Last Earnings DateMar 4, 2025
Next Earnings DateJun 3, 2025
Ex-Dividend Date―
Financial Position
Arch Biopartners as a current ratio of 0.18, with Debt / Equity ratio of -66.35%
Current Ratio0.18
Quick Ratio0.18
Debt to Market Cap0.02
Net Debt to EBITDA-0.78
Interest Coverage Ratio-10.14
Taxes
In the past 12 months, Arch Biopartners has paid -335.83K in taxes.
Income Tax-335.83K
Effective Tax Rate0.08
Enterprise Valuation
Arch Biopartners EV to EBITDA ratio is -32.56, with an EV/FCF ratio of -49.31.
EV to Sales0.00
EV to EBITDA-32.56
EV to Free Cash Flow-49.31
EV to Operating Cash Flow-49.31
Balance Sheet
Arch Biopartners has C$54.85K in cash and marketable securities with C$2.83M in debt, giving a net cash position of C$2.77M billion.
Cash & Marketable SecuritiesC$54.85K
Total DebtC$2.83M
Net CashC$2.77M
Net Cash Per ShareC$0.04
Tangible Book Value Per Share-C$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Arch Biopartners is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-78.59%